Sarepta Therapeutics, Inc. (SRPT) stock
SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3086% below fair value
$14.77−0.36 (-2.38%)
Close on Nov 17, 2026Market cap $1.56BP/E –Yield –
Sarepta Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Sarepta Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $1.97B, down 20.4% year over year. For fiscal 2025 it was $2.20B, up 15.6% from the year before. Over ten years it grew 111.1% a year on average. The highest annual figure on record is $2.20B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.20B | +15.6% |
| FY2024 | Dec 31, 2024 | $1.90B | +53.0% |
| FY2023 | Dec 31, 2023 | $1.24B | +33.3% |
| FY2022 | Dec 31, 2022 | $933.01M | +32.9% |
| FY2021 | Dec 31, 2021 | $701.89M | +30.0% |
| FY2020 | Dec 31, 2020 | $540.10M | +41.8% |
| FY2019 | Dec 31, 2019 | $380.83M | +26.5% |
| FY2018 | Dec 31, 2018 | $301.03M | +94.7% |
| FY2017 | Dec 31, 2017 | $154.58M | +2751.6% |
| FY2016 | Dec 31, 2016 | $5.42M | +332.6% |
| FY2015 | Dec 31, 2015 | $1.25M | -87.2% |
| FY2014 | Dec 31, 2014 | $9.76M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $401.25M | -34.3% |
| Q1 FY2026 | Mar 31, 2026 | $730.80M | -1.9% |
| Q4 FY2025 | Dec 31, 2025 | $442.93M | -32.7% |
| Q3 FY2025 | Sep 30, 2025 | $399.36M | -14.5% |
| Q2 FY2025 | Jun 30, 2025 | $611.09M | +68.4% |
| Q1 FY2025 | Mar 31, 2025 | $744.86M | +80.2% |
| Q4 FY2024 | Dec 31, 2024 | $658.41M | +65.9% |
| Q3 FY2024 | Sep 30, 2024 | $467.17M | +40.8% |
| Q2 FY2024 | Jun 30, 2024 | $362.93M | +38.9% |
| Q1 FY2024 | Mar 31, 2024 | $413.46M | +63.1% |
| Q4 FY2023 | Dec 31, 2023 | $396.78M | +53.5% |
| Q3 FY2023 | Sep 30, 2023 | $331.82M | +44.1% |
| Q2 FY2023 | Jun 30, 2023 | $261.24M | +11.9% |
| Q1 FY2023 | Mar 31, 2023 | $253.50M | +20.2% |
| Q4 FY2022 | Dec 31, 2022 | $258.43M | +28.3% |
| Q3 FY2022 | Sep 30, 2022 | $230.27M | +21.6% |
| Q2 FY2022 | Jun 30, 2022 | $233.49M | +42.3% |
| Q1 FY2022 | Mar 31, 2022 | $210.83M | +43.5% |
| Q4 FY2021 | Dec 31, 2021 | $201.46M | +38.8% |
| Q3 FY2021 | Sep 30, 2021 | $189.41M | +31.6% |
| Q2 FY2021 | Jun 30, 2021 | $164.09M | +19.5% |
| Q1 FY2021 | Mar 31, 2021 | $146.93M | +29.3% |
| Q4 FY2020 | Dec 31, 2020 | $145.14M | +45.0% |
| Q3 FY2020 | Sep 30, 2020 | $143.92M | +45.3% |
| Q2 FY2020 | Jun 30, 2020 | $137.36M | +45.1% |
| Q1 FY2020 | Mar 31, 2020 | $113.67M | +30.6% |
| Q4 FY2019 | Dec 31, 2019 | $100.11M | +18.6% |
| Q3 FY2019 | Sep 30, 2019 | $99.04M | +26.2% |
| Q2 FY2019 | Jun 30, 2019 | $94.67M | +28.7% |
| Q1 FY2019 | Mar 31, 2019 | $87.01M | +34.7% |
| Q4 FY2018 | Dec 31, 2018 | $84.42M | +47.4% |
| Q3 FY2018 | Sep 30, 2018 | $78.49M | +70.8% |
| Q2 FY2018 | Jun 30, 2018 | $73.53M | +110.0% |
| Q1 FY2018 | Mar 31, 2018 | $64.60M | +295.3% |
| Q4 FY2017 | Dec 31, 2017 | $57.28M | +956.6% |
| Q3 FY2017 | Sep 30, 2017 | $45.95M | – |
| Q2 FY2017 | Jun 30, 2017 | $35.01M | – |
| Q1 FY2017 | Mar 31, 2017 | $16.34M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.42M | – |
See a number that looks wrong?